Molecular Classification of Non–Muscle-Invasive Bladder Cancer (pTa Low-Grade, pT1 Low-Grade, and pT1 High-Grade Subgroups) Using Methylation of Tumor-Suppressor.

Slides:

Advertisements

Similar presentations

Measurement of Relative Copy Number of CDKN2A/ARF and CDKN2B in Bladder Cancer by Real-Time Quantitative PCR and Multiplex Ligation-Dependent Probe Amplification.

Advertisements

Nine Novel Germline Gene Variants in the RET Proto-Oncogene Identified in Twelve Unrelated Cases Syed A. Ahmed, Karen Snow-Bailey, W. Edward Highsmith,

Telomerase Activity and Expression of Telomerase RNA Component and Telomerase Catalytic Subunit Gene in Cervical Cancer Kenji Nakano, Elizabeth Watney,

CyclinD1/CyclinD3 Ratio by Real-Time PCR Improves Specificity for the Diagnosis of Mantle Cell Lymphoma Carol D. Jones, Katherine H. Darnell, Roger A.

Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar The.

Duplex Ratio Tests as Diagnostic Biomarkers in Malignant Melanoma

Development and Clinical Validation of a Real-Time PCR Assay for PITX2 DNA Methylation to Predict Prostate-Specific Antigen Recurrence in Prostate Cancer.

PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies Barbara Uhl, Heidrun Gevensleben, Yuri Tolkach,

Statistical Considerations for Immunohistochemistry Panel Development after Gene Expression Profiling of Human Cancers Rebecca A. Betensky, Catherine.

Diego M. Marzese, Dave S. B. Hoon, Kelly K. Chong, Francisco E

Vida Kocbek, Katja Vouk, Nick A. Bersinger, Michael D

In Silico Proficiency Testing for Clinical Next-Generation Sequencing

Volume 186, Issue 5, Pages (November 2011)

Laila C. Schenkel, Charles Schwartz, Cindy Skinner, David I

Laboratory Guidelines for Detection, Interpretation, and Reporting of Maternal Cell Contamination in Prenatal Analyses Narasimhan Nagan, Nicole E. Faulkner,

Eligibility Criteria and Genetic Testing Results from a High-Risk Cohort for Hereditary Breast and Ovarian Cancer Syndrome in Southeastern Ontario Ricardo.

Mark G. Erlander, Xiao-Jun Ma, Nicole C

Molecular Genetics of Pediatric Soft Tissue Tumors

Quantitative Fluorescence in Situ Hybridization and its Ability to Predict Bladder Cancer Recurrence and Progression to Muscle-Invasive Bladder Cancer

Somatic Mutations of PI3K in Early and Advanced Gallbladder Cancer

Joanna Wang, Chetan Bettegowda The Journal of Molecular Diagnostics

Maxim B. Freidin, Neesa Bhudia, Eric Lim, Andrew G

Development and Clinical Validation of a Real-Time PCR Assay for PITX2 DNA Methylation to Predict Prostate-Specific Antigen Recurrence in Prostate Cancer.

Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar

Cornelis J. J. Huijsmans, Jeroen Poodt, Paul H. M. Savelkoul, Mirjam H

Volume 61, Issue 6, Pages (June 2012)

Ken B. Waites, Li Xiao, Vanya Paralanov, Rose M. Viscardi, John I

A Lean Laboratory The Journal of Molecular Diagnostics

Jacquelyn D. Riley, Gary W

Influenza A Subtyping The Journal of Molecular Diagnostics

The History and Impact of Molecular Coding Changes on Coverage and Reimbursement of Molecular Diagnostic Tests Susan J. Hsiao, Mahesh M. Mansukhani,

Patrick R. Murray The Journal of Molecular Diagnostics

Next-Generation Sequencing of the BRCA1 and BRCA2 Genes for the Genetic Diagnostics of Hereditary Breast and/or Ovarian Cancer Daniel Trujillano, Maximilian.

PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies Barbara Uhl, Heidrun Gevensleben, Yuri Tolkach,

William L. Gerald, M.D., Ph.D, 1954–2008

Yuqiu Jiang, Graham Casey, Ian C

Validation of Circulating miRNA Biomarkers for Predicting Lymph Node Metastasis in Gastric Cancer Shine Young Kim, Tae Yong Jeon, Chang In Choi, Dae.

Kyong-Ah Yoon, Sohee Park, Sang Hee Lee, Jin Hee Kim, Jin Soo Lee

Hillary S. Sloane, James P. Landers, Kimberly A. Kelly

Katja Lundgren, Nicholas P

Jamal H. Carter, Samantha N. McNulty, Patrick J. Cimino, Catherine E

Benjamin P. Song, Surbhi Jain, Selena Y. Lin, Quan Chen, Timothy M

Target-Enriched Next-Generation Sequencing Reveals Differences between Primary and Secondary Ovarian Tumors in Formalin-Fixed, Paraffin-Embedded Tissue

BRAF Mutation Testing in Solid Tumors

Skin Biopsy Is a Practical Approach for the Clinical Diagnosis and Molecular Genetic Analysis of X-Linked Alport's Syndrome Fang Wang, Dan Zhao, Jie.

Duplex Ratio Tests as Diagnostic Biomarkers in Malignant Melanoma

The Molecular Pathology of Primary Immunodeficiencies

Vida Kocbek, Katja Vouk, Nick A. Bersinger, Michael D

Diego M. Marzese, Dave S. B. Hoon, Kelly K. Chong, Francisco E

miR-210 Is a Prognostic Marker in Clear Cell Renal Cell Carcinoma

Multiplexed Methylation Profiles of Tumor Suppressor Genes in Bladder Cancer Maria José Cabello, Laura Grau, Noreli Franco, Esteban Orenes, Miguel Alvarez,

Expression Of Human Chorionic Gonadotropin β-Subunit Type I Genes Predicts Adverse Outcome In Renal Cell Carcinoma Kristina Hotakainen, Susanna Lintula,

Retrospective Comparison of Nucleic Acid Sequence–Based Amplification, Real-Time PCR, and Galactomannan Test for Diagnosis of Invasive Aspergillosis

Ayalew Tefferi, Pierre Noel, Curtis A. Hanson

Intratumoral Heterogeneity of MicroRNA Expression in Breast Cancer

847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach Molecular.

Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers Wenhsiang Wen, Wangjuh (Sting) Chen, Nick Xiao, Ryan.

Volume 51, Issue 5, Pages (May 2007)

Examination of Gene Fusion Status in Archival Samples of Alveolar Rhabdomyosarcoma Entered on the Intergroup Rhabdomyosarcoma Study-III Trial Frederic.

MiRNA Profiling Identifies Candidate miRNAs for Bladder Cancer Diagnosis and Clinical Outcome Nadine Ratert, Hellmuth-Alexander Meyer, Monika Jung, Poline.

Inherited Cardiomyopathies

Carrie C. Lubitz, Sareh Parangi, Tammy M. Holm, M

Use of Pyrosequencing of 16S rRNA Fragments to Differentiate between Bacteria Responsible for Neonatal Sepsis Jeanne A. Jordan, Allyson R. Butchko, Mary.

Karen Snow-Bailey, Ph.D., 1961–2006

Custom Design of a GeXP Multiplexed Assay Used to Assess Expression Profiles of Inflammatory Gene Targets in Normal Colon, Polyp, and Tumor Tissue Janice.

Clinical Experience with the Cervista HPV HR Assay

Angiotensin I-Converting Enzyme

Monique A. Johnson, Marvin J. Yoshitomi, C. Sue Richards

Measurement of Relative Copy Number of CDKN2A/ARF and CDKN2B in Bladder Cancer by Real-Time Quantitative PCR and Multiplex Ligation-Dependent Probe Amplification

The History and Impact of Molecular Coding Changes on Coverage and Reimbursement of Molecular Diagnostic Tests Susan J. Hsiao, Mahesh M. Mansukhani,

Presentation transcript:

Molecular Classification of Non–Muscle-Invasive Bladder Cancer (pTa Low-Grade, pT1 Low-Grade, and pT1 High-Grade Subgroups) Using Methylation of Tumor-Suppressor Genes Raquel Sacristan, Carolina Gonzalez, Jesus M. Fernández-Gómez, Florentino Fresno, Safwan Escaf, Marta Sánchez-Carbayo The Journal of Molecular Diagnostics Volume 16, Issue 5, Pages 564-572 (September 2014) DOI: 10.1016/j.jmoldx.2014.04.007 Copyright © 2014 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

Figure 1 Methylation of TSGs as a prognostic biomarker of clinical outcome in patients with noninvasive bladder cancer. Survival analysis indicates that the differential methylation for the genes shown significantly predicts recurrence in all patients (A and B) and in the NMI subgroups of pTaLG (C–E), pT1LG (F–I), and pT1HG (J). N, number of cases; O, number of events during follow up. Survival analysis indicates that the differential methylation for several genes significantly predicts recurrence, in the full NMI series PAX5A (P = 0.01) (A); RB1 (P = 0.008) (B); in pTaLG lesions: PAX5A (P = 0.019) (C), WT1 (P = 0.042) (D), and BRCA1 (P = 0.023) (E); in Pt1ALG: PAX6 (P = 0.044) (F), ATM (P = 0.004) (G), CHFR (P = 0.035) (H), and RB1 (P = 0.007) (I); and in pT1HG for PYCARD (P = 0.035) (J). The Journal of Molecular Diagnostics 2014 16, 564-572DOI: (10.1016/j.jmoldx.2014.04.007) Copyright © 2014 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions